The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Medtronic PLC (NYSE:MDT)

• On April 28, Medtronic announced CE Mark for Stealth AXiS™ surgical system. “Receiving CE mark for the Stealth AXiS™ system marks an important milestone in expanding access to advanced surgical technologies across Europe,” said Oli Prosperi, Vice President, International Commercial, Cranial & Spinal Technologies, Medtronic. “Achieving CE mark in the current regulatory environment, under EU Medical Device Regulation (MDR), underscores our commitment to bringing meaningful innovation into a highly diverse healthcare landscape.” The company's stock fell around 10% over the past month and has a 52-week low of $77.39.
• RSI Value: 28.7
• MDT Price Action: Shares of Medtronic fell 0.7% to close at $77.79 on Tuesday.
• Edge Stock Ratings: 10.45 Momentum score with Value at 29.05.

Option Care Health Inc (NASDAQ:OPCH)        

• On April 30, Option Care Health reported mixed first-quarter financial results and cut its FY26 sales guidance below estimates. “The first quarter reflected a mixed performance for our business, and we are not satisfied with our revenue growth momentum,” commented John C. Rademacher, President & Chief Executive Officer, Option Care Health. The company's stock fell around 21% over the past five days and has a 52-week low of $18.01.
• RSI Value: 28.7
• OPCH Price Action: Shares of Option Care Health rose 0.8% to close at $21.30 on Tuesday.
• Benzinga Pro’s charting tool helped identify the trend in OPCH stock.

Genprex Inc (NASDAQ:GNPX)

• On April 30, Genprex said that the Israel Patent Office granted the company a patent covering the use of Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. The company's stock fell around 39% over the past month and has a 52-week low of $0.86.
• RSI Value: 27.4
• GNPX Price Action: Shares of Genprex fell 5.7% to close at $0.89 on Tuesday.
• Benzinga Pro’s signals feature notified of a potential breakout in GNPX shares.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock